Predictors of response to infliximab in patients with fistulizing Crohn's disease Factores predictivos de respuesta a infliximab en pacientes con enfermedad de Crohn fistulizante

Predictors of response to infliximab in patients with fistulizing Crohn's disease Factores predictivos de respuesta a infliximab en pacientes con enfermedad de Crohn fistulizante

Objective: to evaluate the efficacy and toxicity of infliximab for the treatment of fistulizing Crohn's disease. Methods: consecutive patients with fistulizing Crohn's disease receiving infliximab were prospectively enrolled. Partial response was defined as a reduction of 50% or more from...

Full description

Bibliographic Details
Main Authors:	M. Luna-Chadid, J.L. Pérez Calle, J.L. Mendoza, M. I. Vera, A. F. Bermejo, F. Sánchez, A. López San Román, C. Froilán, V. González-Lara, J. García-Paredes, I. Fernández-Blanco, L. Abreu, B. Casis, J. A. Solís Herruzo, J.P. Gisbert, J. Maté-Jiménez
Format:	Article
Language:	English
Published:	Aran Ediciones 2004-06-01
Series:	Revista Espanola de Enfermedades Digestivas
Subjects:	Enfermedad de Crohn Enfermedad inflamatoria intestinal Infliximab Enfermedad de Crohn fistulizante Fistulas Tratamiento Crohn's disease Inflammatory bowel disease Fistulizing Crohn's disease Fistula Treatment
Online Access:	http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082004000600003

Similar Items

Prognostic factors for the efficacy of infliximab in patients with luminal fistulizing Crohn’s disease
by: Ye Ma, et al.
Published: (2023-03-01)

Infliximab for Anoperineal Lesions in Crohn's Disease: Remission Appears to be Based on Rapid Combination Therapy at High Doses
by: Nadia Fathallah, et al.
Published: (2022-06-01)

Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab
by: You Lim Kim, et al.
Published: (2014-01-01)

Early intestinal obstruction after infliximab therapy in Crohn’s disease
by: Mitsuro Chiba, et al.
Published: (2019-08-01)

Efficacy of adalimumab in patients with crohn's disease and failure to infliximab therapy: a clinical series Eficacia de Adalimumab en pacientes con enfermedad de Crohn y fracaso previo a la terapia con Infliximab: resultados de una serie clínica
by: Patricia Cordero-Ruiz, et al.
Published: (2011-06-01)

Fístula entero-vesical: a propósito de un caso
by: Robson Francisco Ferreira Junior, et al.
Published: (2022-04-01)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease
by: Luis Eduardo Miani Gomes, et al.
Published: (2019-04-01)

Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
by: Yoon Suk Jung, et al.
Published: (2021-01-01)

Cortical Vein Thrombosis after Infliximab Treatment for Crohn’s Disease
by: Saeed Razmeh, et al.
Published: (2021-03-01)

Efficacy of Infliximab for the Treatment of Oral Manifestation of Crohn’s Disease
by: Aibar Aginbay, et al.
Published: (2022-11-01)

The impact of medication belief on adherence to infliximab in patients with Crohn’s disease
by: Shuyan Li, et al.
Published: (2023-08-01)

Fecal Calprotectin at Postinduction Is Capable of Predicting Persistent Remission and Endoscopic Healing after 1 Year of Treatment with Infliximab in Pediatric Patients with Crohn’s Disease
by: Yoo Min Lee, et al.
Published: (2024-05-01)

Proactive monitoring of anti-TNF agents improves follow-up of paediatric patients with Crohn disease
by: Begoña Rodríguez Azor, et al.
Published: (2023-03-01)

Ovarian involvement in Crohn's disease: a rare complication
by: Rosa Saborit, et al.
Published: (2016-02-01)

Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn's disease
by: Carlos Taxonera, et al.

MRI-Based Radiomic Signature Identifying Secondary Loss of Response to Infliximab in Crohn's Disease
by: Jing Feng, et al.
Published: (2022-01-01)

Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn’s disease
by: Kouzhu Zhu, et al.
Published: (2024-08-01)

Gluteal and Presacral Abscess Due to Crohn’s Disease with Multiple Fistulas
by: Hyun Joo Song, et al.
Published: (2024-01-01)

Combined therapy with early initiation of infliximab following drainage of perianal fistulising Crohn’s disease: a retrospective cohort study
by: Ping Zhu, et al.
Published: (2022-01-01)

ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN’S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report
by: Ivaylo Vazharov, et al.
Published: (2016-12-01)

Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
by: Yiyoung Kwon, et al.
Published: (2022-09-01)

The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn’s Disease with Infliximab
by: Marla C. Dubinsky, et al.
Published: (2023-09-01)

The role of proactive therapeutic drug monitoring in guiding infliximab therapeutic optimization in pediatric patients with Crohn's disease: A retrospective study
by: Junya Song, et al.
Published: (2024-12-01)

EFFICACY OFINFLIXIMABIN THE TREATMENTOF CROHN’S DISEASEIN CHILDREN
by: E. G. Tsimbalova, et al.
Published: (2012-01-01)

Disease- and Medication-Specific Differences of the Microbial Spectrum in Perianal Fistulizing Crohn’s Disease—Relevant Aspects for Antibiotic Therapy
by: Matthias Kelm, et al.
Published: (2022-10-01)

Deep-Learning, Radiomics and Clinic Based Fusion Models for Predicting Response to Infliximab in Crohn’s Disease Patients: A Multicentre, Retrospective Study
by: Cai W, et al.
Published: (2024-10-01)

A novel role of the splenic volume in Crohn’s disease: evaluating the efficacy of infliximab
by: Xuan Shi, et al.
Published: (2023-08-01)

Development and validation of a clinical radiomics nomogram to predict secondary loss of response to infliximab in Crohn's disease patients
by: Chao Zhu, et al.
Published: (2023-04-01)

Cephalic Duodenopancreatectomy for Hyperalgic Duodenal Crohn's Disease Fistulized in the Pancreatic Gland
by: Sabra Guellouz, et al.
Published: (2014-03-01)

Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab
by: Jihye Park, et al.
Published: (2023-05-01)

Tracing the historical foundations of infliximab in Crohn’s disease treatment: a cited reference analysis
by: Andy Wai Kan Yeung
Published: (2024-11-01)

A novel role of prognostic nutritional index in predicting the effectiveness of infliximab in Crohn's disease
by: Ziheng Peng, et al.
Published: (2023-12-01)

Diagnostic and treatment recommendations on perianal Crohn's disease Recomendaciones en el manejo diagnóstico y terapéutico de la enfermedad de Crohn fistulosa perianal
by: J. L. Mendoza, et al.
Published: (2005-01-01)

Infliximab-induced psoriasis in a patient with crohn′s disease
by: Iqbal Bukhari, et al.
Published: (2015-01-01)

Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease
by: So Yoon Choi, et al.
Published: (2023-06-01)

Factors Contributing to the Preference of Korean Patients with Crohn’s Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)
Published: (2016-05-01)

Serological Biomarkers of Intestinal Collagen Turnover Identify Early Response to Infliximab Therapy in Patients With Crohn’s Disease
by: Marta S. Alexdottir, et al.
Published: (2022-07-01)

Delayed Infliximab Treatment Affects the Outcomes of Patients With Crohn's Disease During the COVID-19 Epidemic in China: A Propensity Score-Matched Analysis
by: Yong Li, et al.
Published: (2022-01-01)

Doença de Crohn metastática sem manifestação clínica intestinal Metastatic Crohn's disease without intestinal clinical manifestation
by: Marcelo D&#8217;Ambrosio Fernandes, et al.
Published: (2009-12-01)

Epidemiology and Treatment Patterns of Fistulizing Crohn’s Disease in a Large, Real-World Australasian Cohort
by: Jack McNamara, et al.
Published: (2025-01-01)